Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.
Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.
Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.
With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”
Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Read the Full Article on Nature Medicine
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 22:56Matt Simmonds: Having a Really Fabulous Time at the BSH 2026 conference
-
Apr 23, 2026, 22:46Gloria Duah: Not All ‘O Negative’ Blood Is Safe for Every Patient
-
Apr 23, 2026, 22:46Luke McLaughlin: Is Haemophilia a disability? – Vote or Share
-
Apr 23, 2026, 22:44Sonia Wolf: On My Way Back From a Very Invigorating BSH
-
Apr 23, 2026, 22:43Maximo Agustin Schiavone: ‘The Lower the Better’ Is Not a Physiological Principle
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved